CRISPR Therapeutics AG (CRSP) Other Operating Expenses (2019 - 2026)

CRISPR Therapeutics AG has disclosed Other Operating Expenses across 8 years of filings, most recently posting $42.7 million for Q2 2026.

• In Q2 2026, Other Operating Expenses fell 69.77% year-over-year to $42.7 million; the TTM figure through Jun 2026 stood at $270.0 million (up 22.47% YoY), while the FY2025 annual figure was $309.7 million, up 156.68% from the prior year.
• Other Operating Expenses came in at $42.7 million for Q2 2026 at CRISPR Therapeutics AG, down from $45.9 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $141.4 million in Q2 2025 to a low of $6.8 million in Q4 2022.
• Average Other Operating Expenses over 5 years is $46.1 million, with a median of $42.5 million recorded in 2023.
• Year-over-year, Other Operating Expenses tumbled 78.56% in 2022 and jumped 1092.56% in 2025.
• Over 5 years, Other Operating Expenses stood at $6.8 million in 2022, then soared by 193.13% to $20.0 million in 2023, then plunged by 47.92% to $10.4 million in 2024, then jumped by 1092.56% to $124.2 million in 2025, then plunged by 65.59% to $42.7 million in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $42.7 million in Q2 2026, $45.9 million in Q1 2026, and $124.2 million in Q4 2025.